Navigation Links
Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
Date:3/24/2008

Potential NDA Submission in 2009

SEATTLE, March 25 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTA) announced today that enrollment is complete in the phase III EXTEND (PIX301) clinical trial of pixantrone (BBR2278) for patients with relapsed diffuse large B cell non-Hodgkin's lymphoma (NHL). An analysis of the data is expected in the second half of 2008. Based on prior discussions with the U.S. Food and Drug Administration (FDA) the data could provide a registration path for pixantrone if final study results are adequate for submitting a New Drug Application (NDA) with the FDA in early 2009 with a potential approval in 2009. A total of 140 patients were enrolled in the study, 97 patients are currently evaluable according to Histological Intent to Treat, or HITT, criteria and will be included in the final analysis of the study.

"PIX301 examines the effectiveness of pixantrone in patients with relapsed and refractory diffuse large B cell lymphoma, a population where current therapies seldom induce complete remissions," said Jack W. Singer, Chief Medical Officer at CTI. "Based on a blinded current independent assessment of events in the trial we believe we have an adequate sample size of eligible patients to meet the primary objective of the trial."

About the EXTEND (PIX301) Clinical Trial

The EXTEND clinical trial is a phase III single agent trial of pixantrone for patients with relapsed, aggressive non-Hodgkin's lymphoma who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial was conducted at 130 sites in 17 countries. Patients were randomized to receive either pixantrone or another single-agent drug currently used
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
2. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
3. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
4. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
7. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
8. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
9. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
10. IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study
11. Valor Medical Announces First Human Implant of Neucrylate AN(TM) for Treatment of Cerebral Aneurysm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Bedrocan Cannabis Corp., ... independent members to its Board of Directors, enhancing ... of the company, a leading licensed producer of ... Internationally, Bedrocan has 13 years, experience in producing ... seven countries, including Canada. As ...
(Date:8/21/2014)... Aug. 21, 2014   Auxilium Pharmaceuticals, Inc. ... biopharmaceutical company, today announced positive results from a ... histolyticum (or CCH) for the treatment of edematous ... the Phase 2a trial, all three doses of ... showed an improvement in the appearance of cellulite ...
(Date:8/20/2014)... , Aug. 20, 2014  The National Association ... latest results achieved by the real-time, pseudoephedrine (PSE) ... National Precursor Log Exchange (NPLEx), automatically blocks unlawful ... down methamphetamine offenders and make arrests. Data released ... Missouri blocked the sale of more ...
Breaking Medicine Technology:Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Missouri's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... ZURICH, July 16 An innovative ... fibrosis patients has received a second,orphan drug designation ... designation was,granted. The recent designation relates to Burkholderia ... fibrosis patients. For Axentis,Pharma AG of Zurich, Switzerland, ...
... , , , ... are a source of worry for many who fear Alzheimer,s ... July 16 issue of the New England Journal of Medicine suggests that ... to have memory declines in their mid-50s, far earlier than previously thought. ...
Cached Medicine Technology:Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks 2Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks 3Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 2Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 3Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 4Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 5Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 6Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 7
(Date:8/21/2014)... College of Chest Physicians (CHEST) announces the immediate ... Injured During Pandemics and Disasters: CHEST Consensus Statement ... journal CHEST while the global health-care ... The consensus statement aims to guide ethical decision-making, ... crises. The statement was developed by over 100 ...
(Date:8/21/2014)... (Aug. 21, 2014) An international scientific collaboration led ... genetic alterations that may contribute to a rare form ... this rare cancer but other types as well. , ... Health,s Cancer Genome Atlas initiative , completed the ... results today in the journal Cancer Cell . ...
(Date:8/21/2014)... Utah scientists have developed a genetically engineered line of ... new research on epilepsy, Alzheimer,s and other diseases. ... in degree of fluorescence in response to different calcium ... called astrocytes and microglia, to be studied in a ... to decipher how the brain works," said Petr ...
(Date:8/21/2014)... The Mount Sinai Hospital has expanded its ... captures real-time patient feedback and enables staff to make ... now available to admitted patients in the Hospital’s cardiology, ... satisfaction using smartphones. , "We are expanding our ... the timely information we need to respond to patient ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Greater awareness ... to have babies before they are full term has ... some areas of the country, early elective deliveries (EEDs) ... last 20 years, EED is defined as delivery before ... linked to neonatal morbidity and mortality, and offers no ...
Breaking Medicine News(10 mins):Health News:CHEST releases new expert guidance in care of the critically ill and injured 2Health News:Sequence of rare kidney cancer reveals unique alterations involving telomerase 2Health News:Sequence of rare kidney cancer reveals unique alterations involving telomerase 3Health News:Mouse model for epilepsy, Alzheimer's gives window into the working brain 2Health News:The Mount Sinai Hospital Expands Use of Mobile Patient Satisfaction Tool 2Health News:The Mount Sinai Hospital Expands Use of Mobile Patient Satisfaction Tool 3Health News:New “Playbook” Aims to Eliminate Early Elective Deliveries in the United States 2Health News:New “Playbook” Aims to Eliminate Early Elective Deliveries in the United States 3
... window of vulnerability for developing binge eating disorder, especially ... study from the University of North Carolina at Chapel ... long-term study of 100,000 pregnant Norwegian women, the researchers ... eating disorder that began during pregnancy. The research is ...
... By furthering scientists understanding of the molecular mechanisms that ... majority of ineffective antibodies, the work may have implications ... The study was published on September 6, 2007, in ... of the effort to understand how protection against HIV ...
... to Peter B. Ajluni, D.O., American Osteopathic,Association (AOA) President, ... of,Americans without health insurance to 47 million --- as ... --- is a disturbing trend signaling,more must be done ... As lawmakers return this week from the summer recess, ...
... Sept. 6 H.E.A.R.T 911 is a,non-profit, non-sectarian ... fighters and construction trade union workers, all of,whom ... 11th attacks and,surviving family members of those who ... nation-wide to situations that arise during,natural or man-made ...
... promotes free quit-smoking services from ClearWay ... ... a,dramatic new billboard will catch the eye of motorists on Interstate ... a,giant ashtray, the billboard will call attention to QUITPLAN(R) Services,Clearway Minnesota,s ...
... Interactive Workshop Features CML Expert, Jorge Cortes, M.D., ... an,expert on leukemia, will discuss novel treatment approaches for ... CML: A,Model in Cancer Therapy. The program is scheduled ... ET. The program is being offered by The ...
Cached Medicine News:Health News:Pregnancy may increase the risk of developing binge eating disorder 2Health News:Scripps Research scientists shed new light on how antibodies fight HIV 2Health News:Scripps Research scientists shed new light on how antibodies fight HIV 3Health News:Retired NYPD Lieutenants William E. Keegan, Jr., Owen McCaffery and John Moran and Tom Thees, a former COO in the financial industry, announce today the formation of H.E.A.R.T (Healing Emergency Aid Response Team) 911. 2Health News:Award-winning QUITPLAN(R) Services Billboard Debuts in Rogers 2Health News:The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia 2Health News:The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia 3
... It takes powerful technology ... worker safety, and still lower ... SYNCHRON LX20 PRO, offering features ... on any other chemistry analyzer, ...
When it comes to providing speed, accuracy and menu flexibility, the SYNCHRON CX5 PRO has it all. The state-of-the-art CX5 PRO starts with the wide SYNCHRON chemistry menu to create the ideal full-se...
... user-friendly instrument is the ... analyzer for the medium ... a well established nephelometric ... for a wide range ...
Help restore pelvic muscle function with the Prometheus Pathway CTS 2000 evaluation and training system....
Medicine Products: